.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
HealthQuad recently announced a strategic investment in LifeSigns, an innovative AI patient monitoring platform. Specifically, this funding will help the Chennai-based startup expand its international footprint. Consequently, healthcare providers can detect early signs of patient deterioration much faster. LifeSigns integrates medical-grade wearables with a predictive AI engine to improve safety.
For instance, it monitors heart rate, respiration, temperature, blood pressure, and oxygen saturation. Moreover, the system has already served over 325,000 patients across 50 facilities. This technology remarkably reduces code blue incidents by 90 per cent. Additionally, it lowers ICU readmissions by nearly 78 per cent. Clinicians can monitor data remotely through a cloud-based dashboard.
Therefore, clinicians can intervene earlier than ever before to save lives. Furthermore, the company plans to enter Southeast Asia and the GCC region soon. However, the exact investment amount remains undisclosed by the group. This model is globally relevant for the next wave of healthcare technology. Selective integrations will soon strengthen the existing technology stack for better hospital efficiency.
Q1: What specific vitals does the LifeSigns platform monitor?
The platform tracks heart rate, respiration, temperature, blood pressure, and oxygen saturation using medical-grade wearables.
Q2: How does the AI engine improve hospital safety?
It provides safety alerts by flagging early signs of clinical deterioration, which has reduced code blue incidents by 90 per cent.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
HealthQuad invests in LifeSigns, an AI-driven patient monitoring platform that reduces ICU readmissions by 78% and improves clinical outcomes globally....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
